Workflow
波士顿科学(BSX)
icon
搜索文档
Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts
ZACKS· 2024-09-12 07:05
文章核心观点 - 介绍波士顿科学公司(Boston Scientific)的股价表现、盈利预期、分析师评级及估值情况,显示公司具有一定投资潜力 [1][2][3] 股价表现 - 最新交易时段收盘价为82.94美元,较前一日下跌0.14%,表现逊于当日标准普尔500指数1.07%的涨幅、道琼斯指数0.31%的涨幅和纳斯达克指数2.17%的涨幅 [1] - 过去一个月公司股价上涨9.4%,超过医疗板块3.34%和标准普尔500指数2.92%的涨幅 [1] 盈利预期 - 即将发布的财报预计每股收益0.58美元,较上年同期增长16%,预计营收40.3亿美元,较去年同期增长14.34% [1] - 整个财年,Zacks共识预测每股收益2.40美元,营收162.6亿美元,分别较前一年增长17.07%和14.18% [1] 分析师评级 - 近期分析师对公司的预估变化值得关注,预估变化与短期股价直接相关,投资者可利用Zacks Rank模型,该模型考虑预估变化并提供评级系统 [2] - 过去一个月,Zacks共识每股收益预估保持稳定,公司目前Zacks Rank为2(买入) [2] 估值情况 - 公司目前远期市盈率为34.63,行业平均为24.47,公司相对溢价交易 [3] - 公司目前PEG比率为2.75,医疗产品行业平均为2.04 [3] - 医疗产品行业Zacks行业排名为84,处于250多个行业的前34%,Zacks行业排名基于行业内个股平均Zacks Rank计算,研究显示排名前50%的行业表现是后50%的两倍 [3]
Pick Boston Scientific Stock After 130% Gains?
Forbes· 2024-09-10 20:00
文章核心观点 - 波士顿科学公司(Boston Scientific)自2021年初以来股价已经翻了一倍多,主要归因于公司的市销率从5.2倍上升到7.8倍,同时公司收入也增长了54% [1] - 波士顿科学公司是近三年来业绩持续增长的少数公司之一,但其股票表现仍未能持续战胜大盘 [2] - 尽管波士顿科学公司的新产品销售和Watchman产品线带动了收入增长,但公司目前的估值已经较高,未来涨幅空间有限 [3] 公司业务表现 - 波士顿科学公司2020年至2023年收入从99亿美元增长至152亿美元,增长54%,得益于新产品推出和总体手术量上升 [4] - 公司通过收购Baylis、Relievant Medsystems等公司以及持有Acotec的多数股权来推动收入增长 [4] - 公司各业务板块表现良好,心血管业务收入增长50%,医疗器械和神经调节业务收入均增长45% [5] 公司盈利能力 - 波士顿科学公司的营业利润率从2020年的6.9%提升至2023年的17%,调整后每股收益也从0.97美元增长至2.05美元,增长111% [6] - 公司预计2024年每股收益将达2.39美元,同比增长17% [6] 投资评级 - 尽管波士顿科学公司未来三年有望实现低双位数的收入复合增长,但目前其股价已经反映了这些积极因素,投资者可能需要等待股价回调后再考虑入场 [7] - 分析师给出的平均目标价88美元也只有小幅上涨空间,公司当前估值已经较高 [7]
Boston Scientific Corporation (BSX) Wells Fargo 2024 Healthcare Conference (Transcript)
2024-09-05 02:46
会议主要讨论的核心内容 1. 公司在过去10年中的转型和增长情况 [3][4][5] 2. 公司未来5年的发展前景和投资价值 [3][4][5] 3. 公司在并购整合和监管审查方面的策略 [6][7][8][9] 4. 公司在心律管理(EP)业务的发展情况和竞争策略 [24][25][26][37][42][43] 5. 公司在WATCHMAN左心耳封堵器业务的发展情况和OPTION临床试验的意义 [48][49][53][54][55][59][60] 6. 公司在其他业务线如AGENT、TAVR等的发展情况 [65][66][67][69][70][75][76][77][78] 问答环节重要的提问和回答 1. 分析师对公司未来5年的发展前景和投资价值的提问,公司CEO给出了详细的回答 [3][4][5] 2. 分析师对公司在并购整合和监管审查方面的策略的提问,公司CEO和IR给出了回应 [6][7][8][9] 3. 分析师对公司在EP业务的发展情况和竞争策略的提问,公司CEO和医疗总监给出了详细解答 [24][25][26][37][42][43] 4. 分析师对公司在WATCHMAN业务和OPTION临床试验的提问,公司医疗总监给出了回应 [48][49][53][54][55][59][60] 5. 分析师对公司在其他业务线发展情况的提问,公司CEO和IR给出了回应 [65][66][67][69][70][75][76][77][78]
Boston Scientific Shares Rising Higher
FX Empire· 2024-09-04 00:57
EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...
Boston Scientific's ACURATE Prime Aortic Valve System Wins CE Mark
ZACKS· 2024-08-29 21:11
文章核心观点 - 波士顿科学公司(BSX)获得了ACURATE Prime主动脉瓣膜系统的CE认证,这是其结构性心脏产品组合中最新的经导管主动脉瓣膜置换(TAVR)技术 [1] - ACURATE Prime系统在设计和性能方面进行了多项改进,包括增加了一个阀膜尺寸,可以扩大适用于更大解剖结构的患者群体 [2][3] - 这一最新产品有望提升公司介入性心脏治疗业务的表现 [1] 产品特点和优势 - ACURATE Prime系统适用于低、中、高危严重主动脉瓣狭窄患者,可以恢复主动脉瓣的功能和正常血流 [2] - 该系统采用自膨胀、超环形设计,具有增强的支架框架,能够在瓣膜上均匀分布力量,实现稳定贴合 [2] - 产品还提供了重新设计的部署机制,可以帮助医生精准定位瓣膜,提高手术效果 [2] - ACURATE Prime技术简化了手术准备、提升了复杂病例的操作性能,并使瓣膜植入更加快捷可控 [2] - 临床数据显示该瓣膜在更广泛的患者群体中都能实现精准定位,使更多医生可以考虑采用这一技术 [2] - ACURATE Prime适用于主动脉环直径在20.5-29mm之间的患者,并继承了ACURATE neo2平台在临床结果方面的优势,如较低的起搏器和周围漏血率,以及良好的血流动力学表现 [3] - 该瓣膜系统已在全球植入近80,000例患者 [3] 行业前景 - 根据Grand View Research的报告,全球TAVR市场在2023年价值63亿美元,预计到2030年将以7.2%的复合年增长率增长 [4] - 主要驱动因素包括主动脉瓣狭窄患病率上升、最小创伤手术偏好增加,以及老龄人口扩大等 [4] - 瓣膜设计、成像技术和导管技术的创新提高了TAVR的安全性、有效性和可及性,推动了市场的上升趋势 [4] 公司最新业绩 - 公司第二季度财报显示,介入性心脏治疗业务增长强劲,主要得益于冠状动脉治疗和亚太区钙化业务的持续增长 [5] - 结构性心脏瓣膜业务受益于ACURATE neo2在欧洲和拉丁美洲的需求增加 [5] - 心律管理业务的诊断业务超越市场,电生理业务也因FARAPULSE脉冲场消融系统的快速采用而表现出色 [6] 股价表现 - 过去一年,公司股价上涨46.5%,大幅优于同行业12.7%的涨幅 [7] 财务指标 - 过去30天内,分析师对公司2024年每股收益预测保持不变,为2.40美元 [8] - 公司过去4个季度均超出每股收益预期,平均超出幅度为7.2% [8] - 公司目前被评为买入评级 [9]
Boston Scientific Obtains CE Mark for ACURATE Prime™ Aortic Valve System
Prnewswire· 2024-08-27 18:57
MARLBOROUGH, Mass., Aug. 27, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has obtained CE mark for the ACURATE Prime™ Aortic Valve System, the newest transcatheter aortic valve replacement (TAVR) technology in the company's structural heart portfolio. The ACURATE Prime valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a ...
Why Is Boston Scientific (BSX) Up 7.2% Since Last Earnings Report?
ZACKS· 2024-08-24 00:38
It has been about a month since the last earnings report for Boston Scientific (BSX) . Shares have added about 7.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Boston Scientific due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Boston Scientific Q2 Earnings Beat ...
Boston Scientific (BSX) is an Incredible Growth Stock: 3 Reasons Why
ZACKS· 2024-08-23 01:45
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth Style Sco ...
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
ZACKS· 2024-08-21 22:41
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Boston Scientific (BSX) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Boston Scientific is a member of our Medical group, which includes 1018 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank include ...
3 Profitable S&P 500 Stocks With Room to Run: NOW, BSX, COO
ZACKS· 2024-08-21 03:45
The beginning of this month saw choppy trading sessions for equities, with the S&P 500 recording its worst day on Aug 5 since 2022. However, the S&P 500 bounced back last week after positive economic reports on retail sales and initial jobless claims quelled recession apprehensions. The broader index has now notched its eighth straight winning streak on Aug 19 for the first time in 2024.Hence, it is prudent for investors to place bets on profitable and not loss-making stocks of the S&P 500. These stocks are ...